Sirturo Tablets, 100 mg are uncoated white to almost white round biconvex with debossing of "T" over "207" on one side and "100" on the other side. Contraindications. None. . Advise patients to take SIRTURO in combination with other antimycobacterial drugs as prescribed. . SIRTURO ® can cause serious side effects, including:

. MEDICINAL AND BIOLOGICAL SUBSTANCES CAUSING ADVERSE EFFECTS IN THERAPEUTIC USE (E930-E949) SUICIDE AND SELF-INFLICTED INJURY (E950-E959) HOMICIDE AND INJURY PURPOSELY INFLICTED BY OTHER PERSONS . , poisoning, and other adverse effects. Where a code from this section is applicable, it is intended that it shall be used in addition to a code from one of the main chapters of ICD-9-CM, indicating the nature of the . E855.8 Other specified drugs acting on central and autonomic nervous .

Adverse Effects; Therapeutic Use; Pharmacology; Clinical Trials; Biochemical Data Summary; More Info For This Drug. . Other antimycobacterial drugs that have shown in vitro activity against MAC may be added to the regimen of azithromycin plus ethambutol at the discretion of the physician or health care provider. Close. . HUMAN PRESCRIPTION DRUG: Item Code (Source) NDC:60505-2583: Route of Administration: ORAL: DEA Schedule : Active Ingredient/Active Moiety: Ingredient Name .

Table 1. Characteristics of the most frequent specific causes of adverse drug events originating during the hospital stay, selected States, 2011

All patients received a combination of five other antimycobacterial drugs used to treat MDR-TB (i.e., ethionamide, kanamycin, pyrazinamide, ofloxacin, . SIRTURO ® may cause serious side effects, including: . SIRTURO- bedaquiline fumarate tablet . To receive this label RSS feed. Copy the URL below and paste it into your RSS Reader application.

Your search for urine drug screen returned 300+ results. Displaying 121-135: 2015 ICD-9-CM Code V81.4 [convert to ICD-10-CM] Screening for other and unspecified respiratory conditions. Screening for respiratory condition · Screening for respiratory condition done · Screening for respiratory condition done . Chlamydial disease screening done · Chlamydial disease screening done (situation) · Screening for chlamydia (bacterial infection) .

Glaucoma is a leading cause of blindness, and a disease for which treatment methods clearly are available and in common use. . OTHER SPECIFIED ANTIBIOTICS CAUSING ADVERSE EFFECTS IN THERAPEUTIC USE E931.8 OTHER ANTIMYCOBACTERIAL DRUGS CAUSING ADVERSE EFFECTS IN THERAPEUTIC USE E942.5 OTHER VASODILATORS CAUSING ADVERSE EFFECTS IN THERAPEUTIC

Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should use Prograf. Patients receiving the drug should be managed in facilities equipped and . renal, or cardiac function, and of concomitant disease or other drug therapy. Use in Renal Impairment. The pharmacokinetics of Prograf in patients with . as well as to dams during gestation and lactation, was associated with embryolethality and adverse effects on female reproduction .

438.89 Other late effects of cerebrovascular disease 438.9 Unspecified Late Effects Of Cerebrovascular Disease (CVA) 677 Late Effect Of Complication Of Pregnancy, . E930 Antibiotics Causing Adverse Effects In Therapeutic Use . E931.8 Other Antimycobacterial Drugs Causing Adverse Effects In Therapeutic Use